372 related articles for article (PubMed ID: 19756361)
1. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV; Gopalakrishnan A; Anderson LL; Feih JT; Shulgin AT; Daley PF; Ruoho AE
J Neural Transm (Vienna); 2009 Dec; 116(12):1591-9. PubMed ID: 19756361
[TBL] [Abstract][Full Text] [Related]
2. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
3. Abuse liability profile of three substituted tryptamines.
Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
[TBL] [Abstract][Full Text] [Related]
4. Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.
Blough BE; Landavazo A; Decker AM; Partilla JS; Baumann MH; Rothman RB
Psychopharmacology (Berl); 2014 Oct; 231(21):4135-44. PubMed ID: 24800892
[TBL] [Abstract][Full Text] [Related]
5. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM; Eshleman AJ; Forster MJ; Cheng K; Rice KC; Gatch MB
Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
[TBL] [Abstract][Full Text] [Related]
6. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
[TBL] [Abstract][Full Text] [Related]
7. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
[TBL] [Abstract][Full Text] [Related]
8. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
Joolakanti SR; Nickell JR; Janganati V; Zheng G; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2016 May; 26(10):2422-2427. PubMed ID: 27080180
[TBL] [Abstract][Full Text] [Related]
9. Chemical and structural investigation of the paroxetine-human serotonin transporter complex.
Coleman JA; Navratna V; Antermite D; Yang D; Bull JA; Gouaux E
Elife; 2020 Jul; 9():. PubMed ID: 32618269
[TBL] [Abstract][Full Text] [Related]
10. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [
Hankosky ER; Joolakanti SR; Nickell JR; Janganati V; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2017 Dec; 27(24):5467-5472. PubMed ID: 29153425
[TBL] [Abstract][Full Text] [Related]
11. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.
Wang JL; Oya S; Parhi AK; Lieberman BP; Ploessl K; Hou C; Kung HF
Nucl Med Biol; 2010 May; 37(4):479-86. PubMed ID: 20447560
[TBL] [Abstract][Full Text] [Related]
12. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
Zucker M; Weizman A; Rehavi M
Life Sci; 2001 Sep; 69(19):2311-7. PubMed ID: 11669473
[TBL] [Abstract][Full Text] [Related]
13. In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.
Vitale AA; Pomilio AB; Cañellas CO; Vitale MG; Putz EM; Ciprian-Ollivier J
J Nucl Med; 2011 Jun; 52(6):970-7. PubMed ID: 21622895
[TBL] [Abstract][Full Text] [Related]
14. Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.
Glennon RA; Liebowitz SM; Mack EC
J Med Chem; 1978 Aug; 21(8):822-5. PubMed ID: 278843
[TBL] [Abstract][Full Text] [Related]
15. Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.
Coleman JA; Yang D; Zhao Z; Wen PC; Yoshioka C; Tajkhorshid E; Gouaux E
Nature; 2019 May; 569(7754):141-145. PubMed ID: 31019304
[TBL] [Abstract][Full Text] [Related]
16. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
17. Transport and inhibition mechanisms of human VMAT2.
Wu D; Chen Q; Yu Z; Huang B; Zhao J; Wang Y; Su J; Zhou F; Yan R; Li N; Zhao Y; Jiang D
Nature; 2024 Feb; 626(7998):427-434. PubMed ID: 38081299
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
Yang Y; Yu D; Zhu X; Du G; Wang W; Zou F; Wang H; Zhang R; Ye L; Tian J
Eur J Med Chem; 2021 Nov; 224():113718. PubMed ID: 34329999
[TBL] [Abstract][Full Text] [Related]
19. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum.
Naudon L; Leroux-Nicollet I; Boulay D; Costentin J
J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010
[TBL] [Abstract][Full Text] [Related]
20. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.
Lizarraga LE; Cholanians AB; Phan AV; Herndon JM; Lau SS; Monks TJ
Toxicol Sci; 2015 Jan; 143(1):209-19. PubMed ID: 25370842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
